Physician profile
Tahsin Ergin
NPI 1548252406
$4,965.33
in general payments reported to CMS, 2019-2025
15 companies · $383 in 2025
The $383 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $4,030 · 2022: $148 · 2023: $89.47 · 2024: $128 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $600.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $3,984.50 | 2020 | |
| Smith+Nephew, INC. | $423.03 | 2019-2025 | Trigen Intertan, Evos |
| Ferring Pharmaceuticals INC. | $110.18 | 2022-2023 | Euflexxa |
| Bioventus LLC | $88.21 | 2022-2025 | Exogen Ultrasound Bone Healing System |
| Depuy Synthes Sales INC. | $77.38 | 2025 | Na |
| Endo Pharmaceuticals INC. | $48.51 | 2023 | Xiaflex |
| Canon Medical Systems USA, INC. | $45.31 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $32.67 | 2024 | Breztri |
| Stryker Corporation | $30.43 | 2022 | |
| Endo USA, INC. | $28.25 | 2025 | Xiaflex |
| Abbott Laboratories | $25.51 | 2025 | Eterna |
| Pacira Pharmaceuticals Incorporated | $19.56 | 2024 | Iovera, Zilretta, Exparel |
| Avanos Medical | $18.28 | 2019 | |
| Kairos Surgical INC | $17.09 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $16.42 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tahsin Ergin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.